Medical and Pharmaceutical Investors flock to psychedelic start-ups Sovereign wealth funds Temasek and Mubadala engage in discussions to finance biotech ventures Zartasha MushtaqFebruary 12, 2024
Health & Wellness Compass Pathways, Hackensack Meridian Health collaborate on psilocybin treatment research Partnership signals a milestone agreement for innovative treatment solutions Zartasha MushtaqJanuary 19, 2024
Health & Wellness LumiraDX expands the commercial expansion of its diabetes test The test produces results in under seven minutes and improves efficiency and convenience with both screening and monitoring. Joseph MortonNovember 14, 2022
Health & Wellness ChitogenX completes opening phases of rotator cuff clinical trial ChitogenX is a clinical stage regenerative medicine company developing therapeutic tissue repair technologies. Joseph MortonNovember 9, 2022
Medical and Pharmaceutical Amyris and the World Wildlife Fund aim to improve ocean health and shark populations Amyris will support the WWF's drive to push fishers in Ecuador and Peru towards sustainable fishing during the partnership's first year. Joseph MortonOctober 25, 2022
Medical and Pharmaceutical The Mugglehead technology roundup: medical tech and biotechnology edition Here are five biotechnology and medical tech companies pooling their resources to make our lives easier. Joseph MortonOctober 14, 2022
Technology The Mugglehead technology roundup: assorted gems edition Here are five assorted gems for any portfolio. Joseph MortonAugust 26, 2022
Canada Clearmind’s psychoactive drug shows positive results for cocaine use disorder Novel proprietary psychedelic molecule continues to demonstrate potential for treating cocaine dependency Rowan DunneAugust 26, 2022
Health & Wellness Illumina invites genomics firm CEO to chat about future of healthcare Wojcicki will feature on a spotlight session called “Disruption Ahead” wherein she will speak about putting the consumer at the centre of healthcare. Joseph MortonAugust 24, 2022
Cannabis Cybin receives Schedule I DEA license for CYB003 trial New license is the final required step before administering doses to study participants Rowan DunneAugust 17, 2022